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Introduction
Pterygium recurs, most commonly, during the first 4-6 months after surgery, and 97% of recurrences occur within the first year [1, 2, 3] . The above recent meta-analyses have summarized the effects of several adjuvant treatments (conjunctival autograft, mitomycin C (MMC), ciclosporin A, autologous blood, anti-VEGF agents, beta therapy and their combinations) for pterygium. Fonseca et al [1] have found the combination of conjunctival autograft and ciclosporin to be the best treatment to prevent recurrence after primary pterygium surgery, whereas others found intraoperative MMC to be the best adjuvant treatment. However, overall recurrence rates remain rather high (11-38%) [1, 2] . Previously, we have reported on recurrence rates after various surgical techniques for pterygium at immediate (1-3 months) and up to 12 months follow-up points [4] .
A number of studies [5, 6] pointed to the etiological role of human papillomavirus (HPV) that triggers the mechanism of excessive cell proliferation. The disease has been found to be associated also with other oncogenic viruses like herpes simplex virus (HSV), Epstein Barr virus (EBV), and cytomegalovirus (CMV) [7, 8, 9, 10] . The BRAF gene is a major factor for activation of epithelial cell proliferation, and codes for the protein that is involved in the signal transfer from membrane tyrosine kinase receptors to the nucleus [11] . The RAF kinase family consists of ARAF, BRAF and CRAF; normally, CRAF has a dominant role, whereas BRAF has been demonstrated to have a dominant role in a number of tumors [12] . Mutated BRAF relays signals to mitogen-activated protein kinase (MEK) and extracellular signal-regulated kinase (ERK), both kinases playing a pivotal role in initiating cell division. The predominant mutation in the BRAF gene involves thymidine to adenosine transversion at exon 15 nucleotide 1799 (T1799>A), resulting in replacement of valine with glutamic acid at position 600 of amino acid sequence (BRAF V600E ) [11, 12] . BRAFV600E was found in 87% of papillary thyroid carcinomas, 50% of melanomas, and colorectal cancer [13, 14, 15] . Therefore, this study attempted to examine the relationship between (a) the presence of herpes and papilloma viruses, and BRAF V600E mutation and (b) recurrence rates after various surgical techniques for pterygium.
The purpose of this study was to identify the relationship between between (a) recurrence rates after various surgical techniques for pterygium and (b) the presence of herpes viruses (HSV, EBV, and CMV), HPV 6, 11, 16 and 18 and BRAF V600E mutation.
Materials and Methods
The [17] . The groups were statistically similar regarding age, sex, and pterygium stage.
All surgeries were performed under local anesthesia by the same surgical team. Pterygium tissue samples were collected during surgery, placed in containers with saline, marked and stored frozen at -70оС until used for DNA extraction. The PROBA-GS DNA Extraction kit (DNK Tekhnologiya, Russia) was used for viral DNA extraction. Real-time PCR with PCR kits from DNK Tekhnologiya were used to identify HSV, EBV, CMV, and HPV. PCR amplification was performed in a DT-lite real-time PCR system (DNK Tekhnologiya). Genomic DNA was extracted and purified using PureLink Genomic DNA kits (Invitrogen, USA). Real-time PCR was used to detect somatic BRAF mutations at rs113488022 (V600E). Mutation detection was performed using TaqMan Mutation Detection Assays (Thermo Fisher Scientific) in a RealTime PCR System 7500 (Applied Biosystems, USA).
Statistical analysis was performed using MedStat and MedCalc v.15.1 (MedCalc Software bvba). =5.32; р=0.021). Since we have previously demonstrated an association between BRAF V600 mutations and the incidence of pterygium, we examined numbers and rates of pterigium recurrences and BRAF V600 mutations in individual study groups (Table 2) .
Results and Discussion
There was a common trend regarding the relationship between the presence of BRAF V600 mutation and pterygium recurrence in the groups. In group 1, of the 34 patients (69.4%) negative for BRAF V600 mutations, 2 (5.9%) had a recurrence, and of the 15 patients (30.6%) positive for BRAF V600 mutations, 11 (30.6%) had a recurrence. Such a difference was statistically significant for all groups (p<0.01 for each group). Thus, the recurrence rate in BRAF V600 mutation-positive patients was 76.5% compared with 4.2% in BRAF V600 mutation-negative patients in group 2, 81.2% vs 6.1% in group 3, and 77.8% vs 10.7% in group 4. In addition, the same trend, but with somewhat different rates of recurrence was observed in Group 5: of the 31 patients (66.0%) negative for BRAF V600 mutations, only one (3.2%) had a recurrence, and of the 16 patients (34.0%) positive for BRAF V600 mutations, 6 (37.5%) had a recurrence.
Therefore, in the presence of BRAF V600 mutation, compared to the mean recurrence rate in the four groups related to traditional surgical techniques, the recurrence rate in group 5 related to the pterygium surgery technique developed by us were decreased from 77.3% to 37.5% (χ2=116.02; р<0.001), i.e., by 39.8%, or 2.1-fold ( Table  3 ). The obtained results allowed for the calculation of (a) the effect of BRAF V600 mutation on recurrence rate at 1 year after pterygium surgery and (b) the association of BRAF V600 mutation with the disease (Table 4) . We found BRAF V600 mutation to be associated with a recurrence within a year after pterygium surgery (χ2=105.06; p<0.001). The mutation increased the risk of a recurrence within a year after pterygium surgery approximately 35.7-fold (OR=35.72; 95% CI, 15.71-81.24).
Next, we calculated the effect of HSV, EBV, CMV, and HPV 6/11 and 16/ 18 on the development of recurrent pterygium within a year after pterygium surgery. Statistical analysis found no relationship between the distribution of recurrences among the groups, and presence of either individual viruses or their combinations (p>0.1 for all cases).
Since it is possible that HPV may act synergistically with oncogenic mutations [5, 6] , we tried to compare the distributions of recurrences among the cases with four possible combinations of the presence or absence of HPV (-/+) and the presence or absence of BRAF V600 mutation (Table 5) . Of the cases with four possible combinations, the cases with the presence of BRAF V600 in the presence of HPV, and the cases with the presence of BRAF V600 in the absence of HPV, demonstrated the highest recurrence rates (70.4% and 69.1%, respectively), whereas the cases with the absence of BRAF V600 in the presence of HPV, and the cases with the absence of BRAF V600 in the absence of HPV, demonstrated low recurrence rates (7.7% and 2.2%, respectively). These results provide evidence that the presence of HPV infection in pterygium has no effect on the recurrence rate within a year after pterygium surgery.
A study on the possible association of HPV infection and pterygium [6] has reported that the former is not a compulsory etiologic factor but a co-factor increasing the risk of the latter. In the current study, pterygium tissue was found to be infected with a virus in 50.9% of cases, which included HSV, EBV or CMV in 33.6% of cases, and HPV in 34.0% of cases. In addition, HPV 6 and 11 were found mostly in the pterygium stage I or II , and were not found in pterygium stage IV, whereas HPV 16 and 18 were not found in pterygium stage I, and were most common in pterygium stage IV (р=7.95Е-4), which indicates a possible association between HPV and the formation of pterygium.
Detorakis et al [16] proposed a two-hit process of pterygium formation. The first hit is preexisting ultravioletrelated genetic damage, and the second hit is mediated by a viral agent [16] . Our study has demonstrated that pterigium formation may represent a three-hit process: in addition to etiologic impact of exogenous factors (ultraviolet exposure and viruses), there is an impact of an acquired endogenous factor, somatic prooncogenic BRAF V600 mutation, with the latter factor having a crucial role in the development of recurrence. We found that, compared with non-carriers, BRAF V600 mutation carriers had an 8-fold increased risk of developing a recurrence during a year after pterygium surgery.
Conclusion
First, changing from traditional surgical methods (the McReynolds or Arlt method, alone or with adjunctive mitomycin C) to our methodology for pterygium decreased the recurrence rate at 1 year after pterygium surgery by 17.0% (or 2.1-fold), from 31.9% to 14.9% (χ2=5.32; р=0.021).
Second, there was a common trend regarding the relationship between the presence of BRAF V600 mutation and pterygium recurrence in the groups: in the groups with traditional surgical methods, the recurrence rate in BRAF V600 mutation-positive patients varied from 73.3% to 81.2%, whereas the recurrence rate in BRAF V600 mutationnegative patients varied from 4.2% to 10.7% (p < 0.001). The mutation increased the risk of a recurrence within a year after pterygium surgery approximately 35.7-fold (OR=35.72; 95% CI, 15.71-81.24).
Third, changing from traditional surgical methods to our methodology for pterygium decreased the recurrence rate at 1 year after pterygium surgery in BRAF V600 mutation-positive patients by 39.8% (or 2.1-fold), from 77.3% to 37.5% (χ2=116.92; р < 0.01).
Finally, the presence of HSV, EBV, CMV, HPV, or their combinations in pterygium tissue is a risk factor for recurrence after surgical treatment. 
